Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 7/20 | 0.42 |
| ▸ | NAMPT | P43490 | 4/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889469 | 0.79 | RPS6KA2 (0.41) | RPS6KA2NAMPTMEN1KMT2AADORA2A | |
| SCHEMBL7253018 | 0.78 | — | — | |
| SCHEMBL5889538 | 0.77 | RAB9A (0.39) | RPS6KA2NAMPTMEN1KMT2AADORA2A | |
| SCHEMBL5889544 | 0.73 | NAMPT (0.36) | RPS6KA2NAMPTMEN1KMT2AADORA2A | |
| SCHEMBL5889802 | 0.72 | MEN1 (0.37) | RPS6KA2NAMPTMEN1KMT2ALMNA | |
| SCHEMBL5889536 | 0.68 | TERT (0.42) | NAMPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL5889659 | 0.66 | HRAS (0.41) | NAMPTMEN1KMT2ALMNAMAPT | |
| SCHEMBL5889526 | 0.65 | HRAS (0.53) | NAMPTMEN1KMT2ALMNAMAPT | |
| SCHEMBL5889791 | 0.65 | MEN1 (0.38) | NAMPTMEN1KMT2ALMNAMAPT | |
| SCHEMBL5889799 | 0.65 | MEN1 (0.38) | NAMPTMEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064218-B2 | Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GLAXOSMITHKLINE LLC | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | TYR, CYP51A1, ODC1 | RPS6KA2 1675/4885NAMPT 3092/4885FDPS 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.